Evidence map›Paper›PMID 25419038›Full record

ArticleDrugs of the future2011

MODULATION OF AUTOPHAGY AND ITS POTENTIAL FOR CANCER THERAPY.

Sofie Claerhout, Philip L Lorenzi, John N Weinstein, Gordon B Mills

Abstract read
In one paragraph

Article in Drugs of the future, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sofie ClaerhoutDepartment of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Philip L LorenziDepartment of Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
John N WeinsteinDepartment of Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Gordon B MillsDepartment of Systems Biology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

Funding

UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0M
UTMDACC SPORE in Breast CancerP50CA116199 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YU, DIHUA · 2005 to 2009
$11.9M
Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC)U24CA143883 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AKBANI, REHAN, MILLS, GORDON B. · 2009 to 2016
$10.6M
Asparagine Synthetase as a Biomarker for L-asparaginase Rx of Ovarian CancerZ01BC010823 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WEINSTEIN, JOHN N · 2007 to 2008
$749k
Intramural NIH HHS Z01 BC010823Intramural NIH HHS Z99 CA999999NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA116199NCI NIH HHS U24 CA143883
6 · The paper itself

Abstract

Autophagy is a process in which cellular contents are captured in specialized, membrane-bounded vesicles and delivered to lysosomes for final degradation. Most studies support an inherent connection between autophagy and survival, but increasing evidence also suggests an association between autophagy and cell death. The therapeutic potential of targeting the autophagy pathway in cancer seems clear, but specific strategies for achieving successful eradication of cancer cells are less obvious. Recent developments in the fields of autophagy and programmed cell death, nevertheless, have shed light on therapeutic strategies with significant potential. In this review, we provide an overview of the autophagy process, pathways that modulate autophagy, and promising autophagy-based therapeutic strategies for cancer.

Identifiers

PMID25419038
PMCPMC4239665

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.